BLRX stock is attracting buyer interest right before market open on December 5, 2019, after the company released clinical trial data.
BioLineRx announced preliminary data from the triple combination arm of the ongoing Phase 2a COMBAT/KEYNOTE-202 study showing that the combination of BL-8040, Keytruda and chemotherapy shows high response and disease control rates in patients with metastatic pancreatic cancer. The data will be presented at the European Society of Medical Oncology Immuno-Oncology Congress December 11-14 in Geneva, Switzerland. As of September 30, 22 patients were dosed, of which 15 were evaluable. All patients enrolled were originally diagnosed with stage IV metastatic pancreatic adenocarcinoma. Best response for the evaluable population of 15 patients showed 4 partial response and 8 stable disease patients resulting in overall disease control in 12 out of 15 patients; study is ongoing and median progression free survival and overall survival were not yet reached; survival data remain on track for mid-2020; the combination was generally well tolerated, with a safety profile consistent with the individual safety profile of each component alone. Fifteen serious adverse events were reported by 10 patients and 2 patients discontinued the study due to SAEs. Complete study results are expected to be released in mid-2020.